持续监测颅内压与脑氧分压在重型颅脑损伤治疗中的应用
前瞻性随机对照试验纳入70例GCS 4-8分重型颅脑损伤患者,随机分为ICP监测组(n=36)和ICP+PbtO2监测组(n=34)。ICP+PbtO2组在控制ICP<20 mmHg和CPP>60 mmHg基础上调整氧流量维持PbtO2>20 mmHg。结果显示联合监测组平均ICP更低、CPP更高、PaO2更高,3个月和6个月良好预后率及累积生存率均显著优于单纯ICP监测组,PbtO2与GOS评分显著相关。
要点
- 纳入GCS 4-8分重型颅脑损伤患者,ICP+PbtO2组3个月良好预后率67.6% vs ICP组38.9%(P<0.05)。
- 6个月良好预后率联合监测组70.6% vs 单纯ICP组41.7%(P<0.05),累积生存率79.4% vs 55.6%。
- 联合监测组平均ICP 13.4±3.2 mmHg显著低于ICP组18.2±8.3 mmHg(P<0.01)。
- 联合监测组平均CPP 82.1±10.5 mmHg显著高于ICP组74.5±11.6 mmHg(P<0.01)。
- PbtO2与3个月和6个月GOS评分显著相关(r=0.951和0.933,均P<0.01)。
适用人群与场景
- 纳入标准:GCS 4-8分重型颅脑损伤患者,收治于神经外科重症监护病房(NICU)。
- 排除标准:原文未提及。
诊断标准与关键阈值
- 治疗目标:ICP<20 mmHg(1 mmHg=0.133 kPa),CPP>60 mmHg。
- ICP+PbtO2组额外目标:维持PbtO2>20 mmHg。
- 预后评估:GOS评分>3分定义为良好预后。
处置流程与药物剂量
- 第一步:ICP监测组给予ICP监测,按传统治疗控制ICP和CPP,目标ICP<20 mmHg、CPP>60 mmHg。
- 第二步:ICP+PbtO2监测组同时监测ICP和PbtO2,在控制ICP和CPP基础上调整氧流量维持PbtO2>20 mmHg,ICP和CPP目标同ICP监测组。
- 第三步:记录监测期间ICP和PbtO2值,记录CPP、GCS和动脉血气分析结果。
- 第四步:伤后3个月和6个月采用GOS评分比较预后,GOS>3分为良好预后。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 前瞻性随机对照试验,单中心(内蒙古自治区人民医院NICU),2017年1月至2020年5月,纳入70例GCS 4-8分重型颅脑损伤患者,ICP+PbtO2组34例,ICP监测组36例。
- 主要终点:3个月良好预后率ICP+PbtO2组67.6% vs ICP组38.9%(P<0.05);6个月良好预后率70.6% vs 41.7%(P<0.05)。
- 次要终点:平均ICP联合组13.4±3.2 mmHg vs 18.2±8.3 mmHg(P<0.01);平均CPP 82.1±10.5 mmHg vs 74.5±11.6 mmHg(P<0.01);平均PaO2 228.4±93.6 mmHg vs 167.3±81.2 mmHg(P<0.01)。
- GCS评分和PaCO2两组无显著差异(P>0.05)。
- Kaplan-Meier生存曲线:3个月累积生存率85.3% vs 61.1%(χ2=5.171,P=0.023);6个月累积生存率79.4% vs 55.6%(χ2=4.511,P=0.034)。
- 线性回归分析:PbtO2与3个月和6个月GOS评分显著相关(r=0.951和0.933,均P<0.01)。
证据类型、等级与局限
- 证据类型:前瞻性随机对照试验。
- 证据等级或推荐强度:原文未提及。
- 局限:单中心研究,样本量较小(70例),原文未提及盲法及分配隐藏细节。
对床旁实践的改变
- 对GCS 4-8分重型颅脑损伤患者,在ICP监测基础上联合PbtO2监测并维持PbtO2>20 mmHg可能改善3-6个月预后,可考虑作为ICP和CPP管理之外的辅助监测手段。
- 联合监测组通过调整氧流量维持PbtO2>20 mmHg,同时实现更低的平均ICP和更高的平均CPP,提示PbtO2导向治疗可能与更优的颅内生理状态相关。
- 本研究为单中心小样本RCT,结论需多中心大样本验证后再作为常规推荐;原文未提及PbtO2监测的适用与不适用人群细节。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the effects of continuous monitoring intracranial pressure (ICP) and brain oxygen partial pressure (PbtO2) on the prognosis of patients with severe craniocerebral injury.
METHODS: A prospective randomized controlled trial was conducted. Seventy patients with severe craniocerebral injury with a Glasgow coma score (GCS) 4-8 admitted to the neurosurgical intensive care unit (NICU) of the People's Hospital of Inner Mongolia Autonomous Region from January 2017 to May 2020 were enrolled, and they were divided into ICP monitoring group and ICP+PbtO2 monitoring group by random number table. Patients in ICP monitoring group received ICP monitoring and were given traditional treatment of controlling ICP and cerebral perfusion pressure (CPP), the therapeutic target was ICP < 20 mmHg (1 mmHg = 0.133 kPa) and CPP > 60 mmHg. Patients in ICP+PbtO2 monitoring group were given ICP and PbtO2 monitoring at the same time, and oxygen flow was adjusted on the basis of controlling ICP and CPP to maintain the PbtO2 > 20 mmHg, and the therapeutic target of ICP and CPP was the same as the ICP monitoring group. ICP and PbtO2 values were recorded during monitoring in the two groups, the results of CPP, GCS and arterial blood gas analysis were recorded, and the prognosis at 3 months and 6 months after injury was compared by Glasgow outcome scale (GOS) score between the two groups. GOS score > 3 was considered as good prognosis. Kaplan-Meier survival curve was drawn, and the 3-month and 6-month cumulative survival rates of the two groups were analyzed. Linear regression analysis was used to further evaluate the relationship between PbtO2 and GOS score.
RESULTS: Finally, a total of 70 patients with severe craniocerebral injury were enrolled in the analysis, 34 patients received ICP combined with PbtO2 monitoring and guided therapy, and 36 patients received ICP monitoring alone. The average ICP of ICP+PbtO2 monitoring group was significantly lower than that of ICP monitoring group (mmHg: 13.4±3.2 vs. 18.2±8.3, P < 0.01). Although the CPP in both groups was great than 60 mmHg, the average CPP of ICP+PbtO2 monitoring group was significantly higher than that of ICP monitoring group (mmHg: 82.1±10.5 vs. 74.5±11.6, P < 0.01). No significant difference was found in average GCS score or arterial partial pressure of carbon dioxide (PaCO2) between the ICP+PbtO2 monitoring group and ICP monitoring group [GCS score: 5.3±2.3 vs. 5.2±2.2, PaCO2 (mmHg): 33.5±4.8 vs. 32.6±5.2, both P > 0.05]. The average arterial partial pressure of oxygen (PaO2) of ICP+PbtO2 monitoring group was obviously higher than that of ICP monitoring group (mmHg: 228.4±93.6 vs. 167.3±81.2, P < 0.01). Compared with the ICP monitoring group, the good outcome rates of 3 months and 6 months after injury in the ICP+PbtO2 monitoring group were significantly higher (3 months: 67.6% vs. 38.9%, 6 months: 70.6% vs. 41.7%, both P < 0.05). Kaplan-Meier survival curve showed that the 3-month and 6-month cumulative survival rates of ICP+PbtO2 monitoring group were significantly higher than those of ICP monitoring group (3 months: 85.3% vs. 61.1%, Log-Rank test: χ2 = 5.171, P = 0.023; 6 months: 79.4% vs. 55.6%, Log-Rank test: χ2 = 4.511, P = 0.034). Linear regression analysis showed that PbtO2 was significantly correlated with GOS score at 3 months and 6 months after injury in patients with severe craniocerebral injury (r values were 0.951 and 0.933, both P < 0.01).
CONCLUSIONS: PbtO2 compared with ICP monitoring guiding therapy is valuable in improving the prognosis of patients with severe craniocerebral injury. It can improve the prognosis at 3-6 months after injury.
参考来源
- Wang Z, Zhang R, Han Z, et al. [Application of continuous monitoring of intracranial pressure and brain oxygen partial pressure in the treatment of patients with severe craniocerebral injury]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2021. PMID: 34053489. doi:10.3760/cma.j.cn121430-20201106-00700
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。